Abstract
Interleukin (IL)-10 is a pleiotropic cytokine with potent inhibitory effects towards TH-1 cells. IL-10 inhibits secretion of IL-2 and interferon (IFN)γ by T cells and downregulates major histocompatibility complex antigens. A variety of tumor cells secrete IL-10, which can inhibit growth of tumor-specific cytotoxic T cells. IL-10 expression has also been detected in B-cell lymphomas and Hodgkin's disease (HD), and it has been suggested that the cytokine is involved in the pathogenesis of these tumors. We analyzed levels of IL-10 in pretreatment sera of 64 patients with HD and healthy controls using a sensitive enzyme-linked immunosorbent assay. Patients with biopsy-proven HD were enrolled in trials of the German Hodgkin Study Group (GHSG). Elevated IL-10 levels were detected in the sera of nine patients with HD (14.1%) (range 4.5–225.6 pg/ml with a mean of 61.5 pg/ml). IL-10 was not detectable in a control population of healthy volunteers (n=90). Multivariate analyses revealed a significant correlation between elevated IL-10 levels and higher age (over 45 years) but not with any other factors defined by the international prognostic factor score. Patients with elevated IL-10 levels had a significantly lower freedom from treatment failure rate as detected in univariate and multivariate tests. Thus, IL-10 may serve as an independent prognostic factor for HD patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 8 March 1999 / Accepted: 9 September 1999
Rights and permissions
About this article
Cite this article
Bohlen, H., Kessler, M., Sextro, M. et al. Poor clinical outcome of patients with Hodgkin's Disease and elevated interleukin-10 serum levels . Ann Hematol 79, 110–113 (2000). https://doi.org/10.1007/s002770050564
Issue Date:
DOI: https://doi.org/10.1007/s002770050564